Jonathan Wolleben
Stock Analyst at JMP Securities
(4.39)
# 365
Out of 5,005 analysts
227
Total ratings
52%
Success rate
18.74%
Average return
Main Sectors:
Stocks Rated by Jonathan Wolleben
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OCUL Ocular Therapeutix | Maintains: Market Outperform | $20 → $29 | $11.41 | +154.16% | 18 | Oct 1, 2025 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Market Outperform | $86 → $143 | $40.86 | +249.98% | 16 | Sep 26, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Market Outperform | $135 → $142 | $99.02 | +43.41% | 5 | Sep 25, 2025 | |
| KALV KalVista Pharmaceuticals | Maintains: Market Outperform | $27 → $28 | $11.85 | +136.29% | 5 | Sep 12, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Market Outperform | $483 → $485 | $443.01 | +9.48% | 13 | Aug 20, 2025 | |
| LRMR Larimar Therapeutics | Reiterates: Market Outperform | $18 | $4.87 | +269.61% | 13 | Aug 19, 2025 | |
| PHVS Pharvaris | Maintains: Market Outperform | $55 → $52 | $23.39 | +122.32% | 12 | Aug 13, 2025 | |
| ATXS Astria Therapeutics | Maintains: Market Outperform | $25 → $26 | $7.52 | +245.74% | 3 | Aug 13, 2025 | |
| QNCX Quince Therapeutics | Maintains: Market Outperform | $9 → $8 | $1.65 | +384.85% | 2 | Aug 12, 2025 | |
| PTGX Protagonist Therapeutics | Maintains: Market Outperform | $67 → $69 | $64.83 | +6.43% | 12 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $79 → $81 | $72.95 | +11.03% | 11 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $89 → $87 | $27.28 | +218.91% | 10 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $25 → $15 | $3.91 | +283.63% | 13 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $8 | $2.45 | +226.53% | 8 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $21 | $12.90 | +62.79% | 15 | Jun 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $15 | $4.75 | +215.79% | 3 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $19 | $6.05 | +214.05% | 9 | May 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $75 | $4.37 | +1,616.25% | 11 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $38 | $16.69 | +127.68% | 1 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $18 | $7.15 | +151.75% | 8 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $9 | $3.49 | +157.88% | 8 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $55 → $50 | $43.73 | +14.34% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $90 | $84.80 | +6.13% | 1 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $120.22 | - | 1 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $225 | $8.82 | +2,451.02% | 7 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Accumulate | $420 → $485 | $680.50 | -28.73% | 1 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $48 → $32 | $7.29 | +338.96% | 8 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $8 | $0.56 | +1,316.18% | 11 | Apr 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $24 | $33.86 | -29.11% | 1 | May 12, 2023 |
Ocular Therapeutix
Oct 1, 2025
Maintains: Market Outperform
Price Target: $20 → $29
Current: $11.41
Upside: +154.16%
Crinetics Pharmaceuticals
Sep 26, 2025
Maintains: Market Outperform
Price Target: $86 → $143
Current: $40.86
Upside: +249.98%
Rhythm Pharmaceuticals
Sep 25, 2025
Maintains: Market Outperform
Price Target: $135 → $142
Current: $99.02
Upside: +43.41%
KalVista Pharmaceuticals
Sep 12, 2025
Maintains: Market Outperform
Price Target: $27 → $28
Current: $11.85
Upside: +136.29%
Madrigal Pharmaceuticals
Aug 20, 2025
Maintains: Market Outperform
Price Target: $483 → $485
Current: $443.01
Upside: +9.48%
Larimar Therapeutics
Aug 19, 2025
Reiterates: Market Outperform
Price Target: $18
Current: $4.87
Upside: +269.61%
Pharvaris
Aug 13, 2025
Maintains: Market Outperform
Price Target: $55 → $52
Current: $23.39
Upside: +122.32%
Astria Therapeutics
Aug 13, 2025
Maintains: Market Outperform
Price Target: $25 → $26
Current: $7.52
Upside: +245.74%
Quince Therapeutics
Aug 12, 2025
Maintains: Market Outperform
Price Target: $9 → $8
Current: $1.65
Upside: +384.85%
Protagonist Therapeutics
Aug 7, 2025
Maintains: Market Outperform
Price Target: $67 → $69
Current: $64.83
Upside: +6.43%
Aug 7, 2025
Maintains: Market Outperform
Price Target: $79 → $81
Current: $72.95
Upside: +11.03%
Aug 7, 2025
Maintains: Market Outperform
Price Target: $89 → $87
Current: $27.28
Upside: +218.91%
Jul 10, 2025
Maintains: Market Outperform
Price Target: $25 → $15
Current: $3.91
Upside: +283.63%
Jun 27, 2025
Reiterates: Market Outperform
Price Target: $8
Current: $2.45
Upside: +226.53%
Jun 26, 2025
Reiterates: Market Outperform
Price Target: $21
Current: $12.90
Upside: +62.79%
Jun 24, 2025
Reiterates: Market Outperform
Price Target: $15
Current: $4.75
Upside: +215.79%
May 23, 2025
Reiterates: Market Outperform
Price Target: $19
Current: $6.05
Upside: +214.05%
May 16, 2025
Reiterates: Market Outperform
Price Target: $75
Current: $4.37
Upside: +1,616.25%
Apr 10, 2025
Initiates: Market Outperform
Price Target: $38
Current: $16.69
Upside: +127.68%
Mar 3, 2025
Reiterates: Market Outperform
Price Target: $18
Current: $7.15
Upside: +151.75%
Dec 19, 2024
Reiterates: Market Outperform
Price Target: $9
Current: $3.49
Upside: +157.88%
Dec 18, 2024
Maintains: Market Outperform
Price Target: $55 → $50
Current: $43.73
Upside: +14.34%
Dec 16, 2024
Reiterates: Market Outperform
Price Target: $90
Current: $84.80
Upside: +6.13%
Dec 16, 2024
Reiterates: Market Perform
Price Target: n/a
Current: $120.22
Upside: -
Dec 11, 2024
Downgrades: Market Perform
Price Target: $225
Current: $8.82
Upside: +2,451.02%
Nov 13, 2024
Downgrades: Accumulate
Price Target: $420 → $485
Current: $680.50
Upside: -28.73%
Aug 15, 2024
Maintains: Market Outperform
Price Target: $48 → $32
Current: $7.29
Upside: +338.96%
Apr 19, 2024
Reiterates: Market Outperform
Price Target: $8
Current: $0.56
Upside: +1,316.18%
May 12, 2023
Maintains: Outperform
Price Target: $25 → $24
Current: $33.86
Upside: -29.11%